Zacks Research Issues Negative Estimate for PAHC Earnings

Phibro Animal Health Co. (NASDAQ:PAHC) – Equities researchers at Zacks Research lowered their Q2 2025 EPS estimates for Phibro Animal Health in a research note issued to investors on Wednesday, November 20th. Zacks Research analyst R. Department now expects that the company will earn $0.35 per share for the quarter, down from their previous estimate of $0.40. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.59 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q4 2025 earnings at $0.41 EPS, FY2025 earnings at $1.46 EPS, Q2 2026 earnings at $0.46 EPS, Q4 2026 earnings at $0.48 EPS, FY2026 earnings at $1.59 EPS and FY2027 earnings at $2.10 EPS.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, August 28th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. The firm had revenue of $273.16 million for the quarter, compared to the consensus estimate of $262.44 million. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%.

A number of other equities research analysts also recently commented on PAHC. Bank of America lifted their target price on Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research report on Friday, August 30th. Barclays upped their target price on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a research report on Tuesday, November 12th. StockNews.com lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. initiated coverage on Phibro Animal Health in a research report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $16.50.

Phibro Animal Health Stock Down 0.1 %

PAHC stock opened at $23.74 on Friday. Phibro Animal Health has a one year low of $9.49 and a one year high of $25.98. The firm has a market cap of $961.54 million, a PE ratio of 55.26, a PEG ratio of 0.62 and a beta of 0.51. The firm’s 50 day moving average price is $23.13 and its 200-day moving average price is $19.94. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.69 and a current ratio of 3.23.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Wednesday, November 27th will be issued a dividend of $0.12 per share. The ex-dividend date is Wednesday, November 27th. This represents a $0.48 dividend on an annualized basis and a yield of 2.02%. Phibro Animal Health’s payout ratio is currently 111.63%.

Insider Transactions at Phibro Animal Health

In other news, Director E Thomas Corcoran acquired 5,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were bought at an average cost of $20.02 per share, with a total value of $100,100.00. Following the purchase, the director now owns 25,000 shares of the company’s stock, valued at $500,500. This represents a 25.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 50.07% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its position in shares of Phibro Animal Health by 7.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,393 shares of the company’s stock worth $200,000 after buying an additional 1,063 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its position in shares of Phibro Animal Health by 56.0% during the first quarter. Jacobs Levy Equity Management Inc. now owns 79,667 shares of the company’s stock worth $1,030,000 after buying an additional 28,584 shares in the last quarter. CWM LLC lifted its holdings in Phibro Animal Health by 89.8% during the 2nd quarter. CWM LLC now owns 2,188 shares of the company’s stock worth $37,000 after buying an additional 1,035 shares during the last quarter. Cardinal Capital Management boosted its holdings in shares of Phibro Animal Health by 4.7% during the second quarter. Cardinal Capital Management now owns 56,027 shares of the company’s stock valued at $940,000 after acquiring an additional 2,520 shares during the period. Finally, Summit Securities Group LLC bought a new position in shares of Phibro Animal Health in the second quarter worth $83,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.